Our study reveals that a progressive decrease in TXNIP expression is associated with the progression of melanoma towards a metastatic phenotype, whereas high TXNIP expression level associates with tumor regression (RECIST) and with decreased proliferation in patients on MAP kinase targeted therapy. Here, TXNIP is linked to melanoma.